NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SMSPHARMA · data 2026-10-30
SMS Pharmaceuticals Limited
In plain words
Price: 2.6% below its 52-week high of ₹525.
Delivery: 40.6% of traded shares were kept for delivery over the last 10 sessions, against 45.2% over the last 60.
Latest results: a net profit of ₹21 cr for the quarter ended Jun 2026 (+2.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹898 cr |
| Net profit (last 12 months) | ₹102 cr |
| Sales growth, 3 years (yearly) | 19.3% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q4 FY26)
SMSPHARMA Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹237.95 crore, down 4.1% YoY.
Net profit was ₹33 crore, up 62.5% YoY.
Operating margin was 16.8% (16.4% a year ago).
EPS was ₹3.58, up 49.2% YoY.
SMSPHARMA के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹237.95 करोड़; पिछले साल की तुलना में 4.1% की गिरावट।
शुद्ध मुनाफ़ा: ₹33 करोड़; पिछले साल की तुलना में 62.5% की बढ़त।
ऑपरेटिंग मार्जिन: 16.8% (एक साल पहले 16.4%)।
EPS: ₹3.58; पिछले साल की तुलना में 49.2% की बढ़त।
SMSPHARMAના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹237.95 કરોડ; ગયા વર્ષની સરખામણીએ 4.1% ઘટાડો.
ચોખ્ખો નફો: ₹33 કરોડ; ગયા વર્ષની સરખામણીએ 62.5% વધારો.
ઓપરેટિંગ માર્જિન: 16.8% (એક વર્ષ પહેલાં 16.4%).
EPS: ₹3.58; ગયા વર્ષની સરખામણીએ 49.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 35.3% over the last 20 sessions vs 28.9% in the 40 before (1.22x); shares delivered per day 0.83x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 9/15: Verdict "Building", sustained score 60/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 22 Sept 26Dividend Dividend ₹0.4 (ex-date) +3.5% next session
- 7 Feb 26Results Q3 FY26 results: net profit ₹23.5 cr +0.7% next session
- 22 Sept 25Dividend Dividend ₹0.4 (ex-date) -1.9% next session
- 30 May 25Results Q4 FY25 results: net profit ₹20.3 cr -3.8% next session
- 8 Nov 24Results Q2 FY25 results: profit +20.2% YoY -8.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹207 cr | ₹21 cr | +2.0% | 19.8% | 2.23 |
| Sept 2025 | ₹242 cr | ₹25 cr | +79.5% | 20.0% | 2.84 |
| Jun 2025 | ₹196 cr | ₹20 cr | +24.3% | 20.1% | 2.31 |
| Dec 2024 | ₹173 cr | ₹18 cr | +59.9% | 19.2% | 2.15 |
Common questions
What was SMS Pharmaceuticals Limited's latest quarterly profit?
SMS Pharmaceuticals Limited reported a net profit of ₹21 cr for the quarter ended Jun 2026 (+2.0% on the same quarter a year earlier), on revenue of ₹207 cr.
Is SMS Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.46.
What is SMS Pharmaceuticals Limited's P/E ratio?
About 45.4, based on the last 12 months' earnings and a price of ₹511.35 (data 2026-10-30).
What is the 52-week high and low of SMS Pharmaceuticals Limited?
The 52-week high is ₹525 and the 52-week low is ₹270.1.
Similar companies
RPG Life Sciences Limited (RPGLIFE) · Gujarat Themis Biosyn Ltd (GUJTHEM) · Evonile Pharma Limited (NOVARTIND) · Gufic Biosciences Limited (GUFICBIO) · Aarti Drugs Limited (AARTIDRUGS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SMSPHARMA in NSE Scanner →